The goal of this study is to learn what happens to MK-6194 in a healthy person's body when different injection sites are used. Researchers will compare what happens to MK-6194 in a healthy person's body when it is injected into the abdomen and when it is injected into the thigh. Researchers think that the average amount of MK-6194 in a person's body over time will be similar when injected into the thigh or abdomen. They also want to learn if it is safe to inject MK-6194 into the abdomen and thigh, and if people tolerate it.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
16
single injected dose
QPS-MRA, LLC-Early Phase (Site 0001)
South Miami, Florida, United States
Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of MK-6194
Blood samples will be collected to determine the AUC0-Last of MK-6194.
Time frame: At designated timepoints (up to approximately 4 weeks postdose)
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-6194
Blood samples will be collected to determine the AUC0-Inf of MK-6194.
Time frame: At designated timepoints (up to approximately 4 weeks postdose)
Maximum Plasma Concentration (Cmax) of MK-6194
Blood samples will be collected to determine the Cmax of MK-6194.
Time frame: At designated timepoints (up to approximately 4 weeks postdose)
Time to Maximum Plasma Concentration (Tmax) of MK-6194
Blood samples will be collected to determine the Tmax of MK-6194.
Time frame: At designated timepoints (up to approximately 4 weeks postdose)
Apparent Clearance (CL/F) of MK-6194
Blood samples will be collected to determine the CL/F of MK-6194.
Time frame: At designated timepoints (up to approximately 4 weeks postdose)
Apparent Terminal Half-life (t1/2) of MK-6194
Blood samples will be collected to determine the t1/2 of MK-6194.
Time frame: At designated timepoints (up to approximately 4 weeks postdose)
Apparent Volume of Distribution (Vz/F) of MK-6194
Blood samples will be collected to determine the Vz/F of MK-6194.
Time frame: At designated timepoints (up to approximately 4 weeks postdose)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of Participants Who Experience an Adverse Event
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 12 weeks
Number of Participants Who Discontinue Study Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study due to an AE will be reported.
Time frame: Up to approximately 12 weeks